Omrix/Ethicon hemostat advances toward goal
This article was originally published in The Gray Sheet
Executive Summary
Fibrin sealant Evicel, manufactured by Omrix Biopharmaceuticals and marketed by Johnson & Johnson/Ethicon, gains FDA approval for expanded indication May 9. FDA originally licensed the product's predecessor, Crosseal, in 2003 to help control bleeding during liver surgery; the new supplemental biologics license application allows use of the slightly reformulated Evicel in vascular surgery as well. Meanwhile, on March 8, Omrix filed for approval of its end goal for Evicel: an indication for general hemostasis in surgery, which would sanction use in any surgical procedure where bleeding is a problem. An FDA decision is expected by Jan. 8, 2008, the firm says. Evicel, a liquid, competes primarily with Baxter's Tisseel, which is sold in powdered form...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.